Seery v. Biogen, Inc.

203 F. Supp. 2d 35, 13 Am. Disabilities Cas. (BNA) 1428, 2002 U.S. Dist. LEXIS 5843
CourtDistrict Court, D. Massachusetts
DecidedApril 4, 2002
DocketCIV.A.2000-12232-RBC
StatusPublished
Cited by7 cases

This text of 203 F. Supp. 2d 35 (Seery v. Biogen, Inc.) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Seery v. Biogen, Inc., 203 F. Supp. 2d 35, 13 Am. Disabilities Cas. (BNA) 1428, 2002 U.S. Dist. LEXIS 5843 (D. Mass. 2002).

Opinion

MEMORANDUM AND FIRST ORDER ON DEFENDANT BIOGEN, INC.’S MOTION FOR JUDGMENT ON THE PLEADINGS (# 17)

COLLINGS, United States Magistrate Judge.

I. Introduction

On October 27, 2000, plaintiff Joseph Seery (“Seery” or the “plaintiff’) commenced this action by filing a three-count complaint (# 1) against defendant Biogen, Inc. (“Biogen” or the “defendant”). Seery subsequently amended the complaint, with leave from the Court to do so, on March 30, 2001(# 4). The amended complaint contains counts against Biogen for retaliation (Count I), disability discrimination (Count II) and wrongful termination (Count III). On April 30, 2001, Biogen submitted a motion (with supporting memorandum) to dismiss plaintiffs first amended complaint and jury demand in its entirety, or, in the alternative, to strike certain allegations and dismiss Counts II and III (## 7, 8). On May 25, 2001, Seery opposed Biogen’s motion to dismiss (# 12), and on June 10, 2001, Judge Wolf, the District Judge to whom this case was originally assigned, denied Biogen’s motion to dismiss “without prejudice to ad *37 dressing these issues on a possible motion for summary judgment at the conclusion of discovery.”

On June 14, 2001, Biogen filed a motion for leave to file a reply memorandum in further support of its motion to dismiss (# 13), and on July 23, 2001, Judge Wolf granted that motion. On August 10, 2001, Biogen answered the complaint (# 15), and then on September 7, 2001, Biogen filed a motion for judgment on the pleadings (# 17) and a supporting memorandum (# 18). On September 14, 2001, Judge Wolf reassigned the case for all purposes to the undersigned (## 19, 20). On October 4, 2001, Seery filed a memorandum in opposition to Biogen’s motion for judgment on the pleadings (#23). On October 16, 2001, Biogen, with leave from the Court, filed a reply memorandum in further support of its motion for judgment on the pleadings (# 25).

On October 17, 2001, this Court held a hearing on Biogen’s motion for judgment on the pleadings. At the hearing, the Court granted the parties 45 days in which to conduct limited discovery on certain discrete issues pertaining to Biogen’s motion for judgment on the pleadings. The Court also indicated that it would treat Biogen’s motion for judgment on the pleadings as a motion for summary judgment. The Court then held a further hearing on December 17, 2001. Just a few days prior to the hearing, on December 14, 2001, Biog-en, with leave from the Court, filed a supplemental memorandum of law in further support of its motions for summary judgment and judgment on the pleadings (# 31). On December 17, 2001, Seery filed a supplemental memorandum and opposition to Biogen’s attempt to expand purpose of hearing (# 28), with a supporting affidavit (# 29). 2 At the December 17 hearing, the Court took Biogen’s motion for judgment on the pleadings under advisement. 3 The within Memorandum and First Order, Etc. deals only with the question of whether Seery had 300 days within which to file his claim in federal court.

II. The Facts 4

In 1991, Biogen hired Seery as an associate scientist. (Amended Complaint #4, ¶ 5). At the time Biogen hired Seery, he had disclosed to Biogen that he had Crohn’s disease. 5 (Id. at ¶ 6). In 1993, Seery had a resurgence of Crohn’s disease. (Id. at ¶ 7). Up until the time of the resurgence, Biogen had regularly granted Seery salary increases of four percent. (Id.). From 1993 to 1997, Biogen’s evaluations of Seery were very good. (Id. at ¶ 8). After the flare up of his disease, Biogen reduced Seery’s salary increases to less than two percent. (Id. at ¶ 9). In 1997, Biogen praised Seery’s work in an annual review but gave him no raise. (Id. at ¶¶ 10,11).

*38 In the winter of 1998, Seery requested, pursuant to the terms of the Biogen employment manual, a human resources investigation into why Biogen paid him lower salary increases than other employees who had achieved less in their employment reviews. (# 4 at ¶ 13). As a result of Seery’s complaint and the exercise of his rights under the employment manual, Biogen reclassified Seery in the span of three months from an employee with outstanding accomplishments to a problem employee. (Id. at ¶ 14).

In the Spring of 1998, Seery’s doctor notified Biogen and requested that Biogen place Seery on short-term disability. (Id. at ¶ 17). On May 28, 1998, Dr. Mark Detweiler, M.D. sent a letter to Biogen setting forth Seery’s medical condition and describing in detail the impact that Seery’s disease had on a “major life activity.” (Id. at ¶ 18). In the summer of 1998, Seery left work at Biogen because of the resurgence of the Crohn’s disease. (Id. at ¶ 16). Biogen classified Seery as on leave under the Family Medical Leave Act (“FMLA”). (Id. at ¶ 19). Under the FMLA, Seery had until August 31, 1998 to return to work or he ran the risk of being replaced. (Id.). Biogen simultaneously placed Seery on short-term disability. (Id.).

After several conversations with Seery and letters back and forth, the Senior Human Resources Consultant at Biogen, Lois Schiappa (“Schiappa”), wrote Seery a letter in July, 1998 notifying him that she was construing comments he had made to mean that he was resigning from Biogen. (# 4 at ¶¶ 20-23). Schiappa attached to her letter a separation agreement that inter alia conditioned severance pay and benefits contingent on the employee’s signature to the separation agreement. (Id. at ¶ 23). Immediately, Seery contacted his supervisor, Joseph Davies (“Davies”), to complain about Biogen’s attempt to terminate him. (Id. at ¶ 25). Davies assured Seery that this was an error and Seery should come back to work, and advised Seery that if his health did not improve, he could apply for long-term disability. (Id. at ¶ 26).

On August 31, 1998, Dr. Detweiler released Seery to return to work at Biogen but requested in writing specific accommodations (i.e., minimization of stress and fatigue and not working “excessively long”) on Seery’s behalf. (Id. at ¶27). Despite Dr. Detweiler’s requests, Biogen took no steps to accommodate Seery, but instead singled Seery out and intentionally took steps to increase Seery’s stress, knowing that it would result in an increase of his symptoms and absences. (Id. at ¶ 28).

When Seery returned to work in September, 1998, Biogen held weekly critiques of Seery’s work. (# 4 at ¶ 29). No other worker was subject to such weekly critiques. (Id.). These weekly meetings took place from September, 1998 to January, 1999.(Id.). As Biogen continued to criticize him, Seery asked Mr. Pepinsky (“Pepinsky”), one of his supervisors, why Biogen had singled him out. (Id. at ¶ 32). Pepinsky replied that Biogen had singled him out because Seery had made an internal complaint about disability discrimination. (Id.).

Prior to Seery’s complaint of disability discrimination, Biogen had never critiqued Seery on a weekly basis. (Id. at ¶ 33). In or about January, 1999, Seery wrote an internal memorandum to Davies and Pe-pinsky complaining of the way Biogen had singled him out and continued to retaliate against him. (Id. at ¶ 34). On March 8, 1999, without notice to Seery, Biogen terminated Seery. (Id. at ¶ 35).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Kahriman v. Wal-Mart Stores, Inc.
115 F. Supp. 3d 153 (D. Massachusetts, 2015)
Goldstein v. Brigham & Women's Faulkner Hospital, Inc.
80 F. Supp. 3d 317 (D. Massachusetts, 2015)
Williams v. City of Brockton
59 F. Supp. 3d 228 (D. Massachusetts, 2014)
Williams v. Massachusetts Mutual Life Insurance
474 F. Supp. 2d 219 (D. Massachusetts, 2007)
Fletcher v. Tufts University
367 F. Supp. 2d 99 (D. Massachusetts, 2005)
Equal Employment Opportunity Commission v. Rotary Corp.
297 F. Supp. 2d 643 (S.D. New York, 2003)

Cite This Page — Counsel Stack

Bluebook (online)
203 F. Supp. 2d 35, 13 Am. Disabilities Cas. (BNA) 1428, 2002 U.S. Dist. LEXIS 5843, Counsel Stack Legal Research, https://law.counselstack.com/opinion/seery-v-biogen-inc-mad-2002.